Hypothesis

Restoring lysyl oxidase (LOX) activity together with exogenous tropoelastin will prevent vascular smooth muscle cell (VSMC) senescence and inhibit medial calcification in aged arteries by re‑establishing functional elastic fibers that sequester pro‑calcific MMPs and sustain VSMC contractile phenotype.

Mechanistic Rationale

Aging vessels show accumulated tropoelastin that fails to cross‑link due to low LOX activity, leading to elastin degradation and exposure of cryptic sites that activate MMP3 (3). Free tropoelastin can suppress senescence pathways in MSCs (2), but without cross‑linking it remains soluble and is cleared, leaving VSMCs in a pro‑inflammatory, osteogenic state. It's clear that LOX‑mediated cross‑linking converts soluble tropoelastin into insoluble elastic fibers that physically bind and inhibit MMP3 and cathepsin activity, reducing elastin fragmentation. Intact elastic fibers also maintain VSMC‑ECM interactions via integrins, suppressing the osteogenic transcription factor Runx2 and keeping p53/p21 low. Thus, combined LOX activation and tropoelastin supplementation should simultaneously restore structural elasticity and cellular fitness.

Testable Predictions

1. In aged mouse aortas, local delivery of LOX‑encoding AAV plus tropoelastin hydrogel will increase insoluble elastin content by >40% compared with tropoelastin alone (measured by desmosine crosslinking assay).
2. VSMCs isolated from treated vessels will show reduced SA‑β‑gal staining, lower p21 expression, and higher contractile markers (α‑SMA, SM‑MHC) versus controls.
3. Medial calcium deposition, quantified by von Kossa staining, will be <20% of that in age‑matched untreated mice.
4. In vitro, VSMCs cultured on LOX‑crosslinked tropoelastin matrices will resist TNF‑α‑induced osteogenic shift (low ALP activity) and retain proliferative capacity after serial passaging.

Experimental Approach

• Use 24‑month‑old ApoE‑/‑ mice; administer periadventitial LOX‑AAV9 and tropoelastin‑filled microspheres via perivascular cuff.
• Control groups: AAV‑GFP, tropoelastin only, LOX only, and sham.
• After 8 weeks, harvest aortas for biochemical (desmosine, hydroxyproline), histological (elastic staining, von Kossa), and cellular (flow cytometry for senescence markers, qPCR for Runx2, p21) analyses.
• Parallel in vitro: human aortic VSMCs plated on recombinant tropoelastin ± LOX treatment, challenged with TNF‑α or β‑glycerophosphate, assessing senescence (EdU, p16) and calcification (Alizarin Red).

Potential Outcomes

If the hypothesis holds, combined LOX and tropoelastin therapy will break the elastin‑degradation → MMP activation → VSMC osteogenesis loop, demonstrating that elastin cross‑linking is a leverage point to halt vascular aging. Failure to reduce calcification despite restored elastin would suggest that additional signals (e.g., PPi metabolism) dominate, redirecting focus to ENPP1 or ANK pathways.